ANTX news

Antares Capital Credit Advisers has agreed to waive base management and incentive fees for Antares Strategic Credit Fund II for the fiscal year 2027. This waiver benefits the Fund's performance.

AN2 Therapeutics announced positive results for AN2-502998, achieving 100% parasite elimination in nonhuman primates with a favorable safety profile in Phase 1 testing. The company plans to advance the oral CPSF3 inhibitor to Phase 2 studies for chronic Chagas disease, addressing a significant unmet…

Anteris Technologies Global Corp. entered into a Common Stock Sales Agreement with TD Securities to issue up to $250 million in shares through an at-the-market offering. The agreement provides the company with flexible capital raising capacity under its existing S-3 registration statement.